Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.
By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placeboAcoramidis significantly reduc...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 pr...
UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $72 to $82.
https://www.bloomberg.com/news/articles/2025-09-11/bridgebio-says-pfizer-alnylam-aren-t-playing-fair-in-blockbuster-race?embedd...
80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal referen...
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $5...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 pr...
